 Home > Medical News >

Medical Research Articles

FDA grants Galderma's nemolizumab breakthrough therapy designation

 Time of Update: 2020-06-07

vegf signaling pathway grc conference phase engineering tsh receptor antibody iodine phase diagram

recently, Galderma company (http:// announced that the U.S FDA (http:// has granted the company the development of the "first-in-class" IL-31 receptor alpha monoclonal antibody nemolizumab bre
FDA accepts listing application for oberic acid treatment for non-alcoholic fatty hepatitis

 Time of Update: 2020-06-07

liver fibrosis reversal fatty liver nutrition year glp 1 agonist supplements fda approved

recently, Intercept announced The FDA (http:// has accepted a market ingressation application for the treatment of non-alcoholic fatty hepatitis (NASH) for liver fibrosis and has been qualified f
FDA approves GlaxoSmithKline niraparib for treatment of terminal ovarian cancer

 Time of Update: 2020-06-07

1 2 decoder vaccines fda approved anti allergic drugs 3 types gas red 1 2

Today, the U.S FDA (http:// announced that it has approved GlaxoSmithKline (GSK) company (http:// niraparib(name Zejula) extended indications for the treatment of patients with advanced ovaria
FDA approves an application for license for complementary biologics from Romiplostim

 Time of Update: 2020-06-07

1 6 symbol 1 3 5 trimethoxybenzene 2.1 1 dig 6 11 1 octen 3

recently, biotech giant Amgen announced that the u.S Food and Drug (http:// Administration ( FDA http:// ) has approved a license application for supplementary biologics (sBLA) The sBLA was ba
Seattle's oral small molecule tyrosine kinase inhibitor tucatinib Phase 3 trial reaches primary and secondary endpoints

 Time of Update: 2020-06-07

progesterone positive breast cancer parkinson's treatment drug factor 9 solid phase brain eating disease

today, Seattle Genetics (http:// announced that its HER-specific oral small molecule tyrosine kinase inhibitor tucatinib, in the treatment of HER2-positive metastatic breast cancer patients in th
Zhengda Tianqing anti-tumor drug injection with hydrochloric acid benzostin has been issued by the State Drug Administration drug registration approval

 Time of Update: 2020-06-07

eddp drug azo drug biology group topiramate drug class group streptococcus

recently, China Bio Pharmaceutical (http:// issued a notice that affiliated company (http:// Zhengda Tianqing Pharmaceutical Group, the anti-tumor drug injection with hydrochloric acid benzodi
GSK developed the triavement of chronic obstructive pulmonary disease Trelegy Ellipta approved by the National Drug Administration for listing

 Time of Update: 2020-06-07

ibuprofen anti inflammatory onion anti inflammatory still's disease treatment history celiac disease a cabinets

Recently, GSK developed the chronic obstructive pulmonary disease (COPD) tri-therapy fluorobutikason ume bromoquine Verantro inhalation powder mist agent (Trelegy Ellipta) approved by the State Drug
Baxter Squibb CC-486 Maintenance Therapy Treats AML Patients In Phase 3 Key Trials Get Positive Results

 Time of Update: 2020-06-07

malaria treatment japanese hair treatment telomerase cancer cells stormwater treatment atg treatment

today, The (http:// of Baxter's Squibb Company announced that its CC-486, as a maintenance therapy, achieved a statistically significant improvement in total survival (OS) and non-recurrent survi
MHLW approves Alexion's Soliris (eculizumab) for a new indication

 Time of Update: 2020-06-07

supplements fda approved curcumin drug interactions zoloft drug benadryl drug test topamax drug class

Recently, Alexion company (http:// announced that the Ministry of Health, Labour and Welfare (MHLW) has approved a new indication of Soliris (eculizumab) for the treatment of anti-water channel p
China's State Drug Administration approves application for new drug ® by Astellas Acostin

 Time of Update: 2020-06-07

benadryl drug t4 total high lamictal drug interactions high dose probiotics norco drug class

Today, the http:// Group of the Pharmaceuticals (http:// announced that china's national Drug (http:// Supervisory Authority on November 18 approved the listing of the (http:// ) of the of
FDA U.S. Approves APR APR-TD011 Research Drug for Large Herpes Epidermis to Be Certified as Orphan Drug

 Time of Update: 2020-06-07

vitamins wound healing infection treatment physical properties quartz fda government agency what 1 3

Recently, the (http:// of the Research of the Pharmaceutical (http:// of the Swiss APR Applied Pharmaceutical s (http:// announced that the U.S Food and Medicines (http:// Administration (
Lilly IL-17 inhibitor Taltz (ixekizumab) two clinical trials reach primary and secondary endpoint

 Time of Update: 2020-06-07

anti vitamin anti inflammatory anti dna antibody cell signaling pathway 2 3 dibromobutane

today, Eli Lilly (http:// announced that its IL-17 inhibitor Taltz (ixekizumab) has reached its primary and all critical secondary in two clinical trials (http:// treating patients with active
European Commission approves two options for treating HNSCC patients in Mercadon Keytruda

 Time of Update: 2020-06-07

carcinoma axid generic name aripiprazole generic name namzaric generic name nanotechnology cancer treatment

recently, Mersadon announced that the European Commission (EC) has approved two options for Keytruda (Corida, generic name: pembrolizumab, Pablozumab), a first-line treatment of patients with metast
Takeda releases latest data on phase 3 clinical trials of the quadnage dengue vaccine TAK-003

 Time of Update: 2020-06-07

flu vaccine effectiveness type 1 water ind clinical trial typhim vi vaccine www seesaw com

recently, Takeda company (http:// released the latest data from its quadrat dengue vaccine, TAK-003, in the key phase 3 clinical trial (http:// TIDES THE OVERALL VACCINE EFFICACY (VE) OF TAK-
Inovio announces that its INO-5401 combination therapy extends progression-free survival in Phase 1/2 clinical trials treating GBM

 Time of Update: 2020-06-07

clinical trial regulation stage 2 thyroid cancer cea pancreatic cancer serous ovarian cancer treatment data

Today, Inovio Pharmaceuticals (http:// announced that it is working on T-cell activation immunotherapy INO-5401, which is composed of immunoactive agent INO-9012, Libtayo (cemiplimab) Combined th
FDA approves Novartis Adakveo (crizanlizumab, also known as SEG101) for listing

 Time of Update: 2020-06-07

abundant white blood cell terlipressin fda approval phentermine fda approved mitosis cancer cells 2 white pill

recently, Novartis (http:// announced that the U.S FDA (http:// approved the launch of its potential heavy-duty therapy, Adaklizumab, also known as SEG101, to reduce the frequency of vascular
Trovagene PLK1 inhibitor onvansertib (PCM-075) obtains positive early trial data

 Time of Update: 2020-06-07

kras g12c mutation viral gene therapy selective catalytic reduction pd 1 inhibitor acute blood loss

today, Trovagene (http:// announced that it had obtained positive experimental early data in the treatment of 1b/2 clinical trial strial sin (http:// ) in patients with metastatic colorectal ca
Yan Jian and Alkermes jointly developed Vumerity (diroximel fumarate) with provisional FDA approval

 Time of Update: 2020-06-07

avobenzone side effects resveratrol side effects gas drug drug digest diphenhydramine drug test

recently, Biogen and Alkermes company (http:// to develop a new recurrent type of multiple sclerosis (MS) new treatment, Vumerity (diroximel fumarate), received provisional approval for the FDA
Phase Libtayo clinical trials developed by Regenerative Element and Sanofi show good results

 Time of Update: 2020-06-07

1 3 cyclohexanedione clinical trials glioblastoma libtayo fda approval united states industries monoclonal gammopathy treatment

Regeneron company (http:// recently announced that its PD-1 inhibitor Libalo,developed with Sanofi, as a single-drug therapy, has shown significantly better results in the first-stage treatment o
Kadmon's key trial of oral selective ROCK2 inhibitor KD025 reached the main endpoint

 Time of Update: 2020-06-07

lyme disease test cells immune system immune system cells corticosteroids albendazole 200 mg

today, Kadmon announced that its use in the treatment of chronic transplant anti-host disease (cGVHD) in the study of oral selective ROCK2 inhibitor KD025, in the critical test (http:// ROCKstar

Go to Page

Medical Research Articles

FDA grants Galderma's nemolizumab breakthrough therapy designation

FDA accepts listing application for oberic acid treatment for non-alcoholic fatty hepatitis

FDA approves GlaxoSmithKline niraparib for treatment of terminal ovarian cancer

FDA approves an application for license for complementary biologics from Romiplostim

Seattle's oral small molecule tyrosine kinase inhibitor tucatinib Phase 3 trial reaches primary and secondary endpoints

Zhengda Tianqing anti-tumor drug injection with hydrochloric acid benzostin has been issued by the State Drug Administration drug registration approval

GSK developed the triavement of chronic obstructive pulmonary disease Trelegy Ellipta approved by the National Drug Administration for listing

Baxter Squibb CC-486 Maintenance Therapy Treats AML Patients In Phase 3 Key Trials Get Positive Results

MHLW approves Alexion's Soliris (eculizumab) for a new indication

China's State Drug Administration approves application for new drug ® by Astellas Acostin

FDA U.S. Approves APR APR-TD011 Research Drug for Large Herpes Epidermis to Be Certified as Orphan Drug

Lilly IL-17 inhibitor Taltz (ixekizumab) two clinical trials reach primary and secondary endpoint

European Commission approves two options for treating HNSCC patients in Mercadon Keytruda

Takeda releases latest data on phase 3 clinical trials of the quadnage dengue vaccine TAK-003

Inovio announces that its INO-5401 combination therapy extends progression-free survival in Phase 1/2 clinical trials treating GBM

FDA approves Novartis Adakveo (crizanlizumab, also known as SEG101) for listing

Trovagene PLK1 inhibitor onvansertib (PCM-075) obtains positive early trial data

Yan Jian and Alkermes jointly developed Vumerity (diroximel fumarate) with provisional FDA approval

Phase Libtayo clinical trials developed by Regenerative Element and Sanofi show good results

Kadmon's key trial of oral selective ROCK2 inhibitor KD025 reached the main endpoint